Correlation of major depressive disorder symptoms with FKBP5 but not FKBP4 expression in human immunodeficiency virusinfected individuals

Journal of NeuroVirology

Volumn 16, Issue 5, 2010, Pages 399-404

  Tatro, Erick T ^a   Nguyen, Timothy B ^b   Bousman, Chad A ^a   Masliah, Eliezer ^c   Grant, Igor ^a   Atkinson, J Hampton ^a   Everall, Ian P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FKBP4; FKBP5; Gene expression; Genotyping; HIV; Human immunodeficiency virus; Major depression; Major depressive disorder

Indexed keywords

ARTICLE; BECK DEPRESSION INVENTORY; BLOOD DONOR; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FKBP4 GENE; FKBP5 GENE; GENE; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL;

COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FEMALE; GENE EXPRESSION; GENOTYPE; HIV INFECTIONS; HOMOZYGOTE; HUMANS; MALE; TACROLIMUS BINDING PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77957245128     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.3109/13550284.2010.504248     Document Type: Article

References (24)

1. Binder E (2009). The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 34S: S186-S195.
2. Beck A, Brown G (1996). BDI-II manual. San Antonio, TX: The Psychological Corporation.
3. Binder EB, Bradley RG, Liu W, Epstein MP, Deveau TC, Mercer KB, Tang Y, Gillespie CF, Heim CM, Nemeroff CB, Schwartz AC, Cubells JF, Ressler KJ (2008). Association of FKBP5 polymorphisms and childhood abuse with risk of posttraumatic stress disorder symptoms in adults. JAMA 299: 1291-1305. (Pubitemid 351439075)
4. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Bozzette SA, Ortiz-Barron L, Shapiro M (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 58: 721-728. (Pubitemid 32717795)
5. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, Nickel T, Kunzel HE, Fuchs B, Majer M, Pfennig A, Kern N, Brunner J, Modell S, Baghai T, Deiml T, Zill P, Bondy B, Rupprecht R, Messer T, Kohnlein O, Dabitz H, Bruckl T, Muller N, Pfister H, Lieb R, Mueller JC, Lohmussaar E, Strom TM, Bettecken T, Meitinger T, Uhr M, Rein T, Holsboer F, Muller-Myhsok B (2004). Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36: 1319-1325. (Pubitemid 39577942)
6. CHARTER Group (2009). CHARTER variables of interest- cross sectional complete. Technical report. La Jolla, CA: University of California San Diego. Available at:https:// www.charterresource.ucsd.edu/images/Mimages/x-sect-cohort- rep.pdf.
7. Chittiprol S, Shetty KT, Kumar AM, Bhimasenarao RS, Satishchandra P, Subbakrishna DK, Desai A, Ravi V, Satish KS, Gonzalez L, Kumar M (2007). HPA axis activity and neuropathogenesis in HIV-1 clade C infection. Front Biosci 12: 1271-1277. (Pubitemid 46846832)
8. Carey CL, Woods SP, Gonzalez R, Conover E, Marcotte TD, Grant I, Heaton RK (2004). Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26: 307-319. (Pubitemid 39277061)
9. Davies TH, Ning YM, Sanchez ER (2002). A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem 277: 4597-4600.
10. Everall IP, Salaria S, Atkinson JH, Young C, Corbeil J, Grant I, Masliah E, HNRC (HIV Neurobehavioral Research Center) (2006). Diminished somatostatin gene expression in individuals with HIV and major depressive disorder. Neurology 67: 1867-1869. (Pubitemid 44900773)
11. Heuser I, Yassouridis A, Holsboer F (1994). The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res 28: 341-356. (Pubitemid 24370022)
12. Kendler K (1995). Genetic epidemiology in psychiatry: taking both genes and environment seriously. Arch Gen Psychiatry 15: 895-899.
13. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS, National Comorbidity Survey Replication (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105. (Pubitemid 37432885)
14. Kirchheiner J, Lorch R, Lebedeva E, Seeringer A, Roots I, Sasse J, Brockmller J (2008). Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics 9: 841-846.
15. Koenen KC, Saxe G, Purcell S, Smoller JW, Bartholomew D, Miller A, Hall E, Kaplow J, Bosquet M, Moulton S, Baldwin C (2005). Polymorphisms in FKBP5 are associated with peritraumatic dissociation in medically injured children. Mol Psychiatry 10: 1058-1059. (Pubitemid 43251094)
16. Lekman M, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJM, Lipsky R, Wisniewski SR, Manji H, McMahon FJ, Paddock S (2008). The FKBP5-gene in depression and treatment response-an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort. Biol Psychiatry 63: 1103-1110.
17. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 49: 391-404. (Pubitemid 32234301)
18. Sarginson J, Lazzeroni L, Ryan H, Schatzberg A, Murphy G (2010). FKBP5 polymorphisms and antidepressant response in geriatric depression. Am J Med Genet B 153B: 554-560.
19. Tsatsanis C, Dermitzaki E, Venihaki M, Chatzaki E, Minas V, Gravanis A, Margioris AN (2007). The corticotropin- releasing factor (CRF) family of peptides as local modulators of adrenal function. Cell Mol Life Sci 64: 1638-1655. (Pubitemid 47036937)
20. Tatro ET, Everall IP, Kaul M, Achim CL (2009a). Modulation of glucocorticoid receptor nuclear translocation in neurons by immunophilins FKBP51 and FKBP52: implications for major depressive disorder. Brain Res 1286: 1-12.
21. Tatro E, Everall I, Masliah E, Hult B, Lucero G, Chana G, Soontornniyomkij V, Achim C, HNRC (2009b). Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J Neuroimmune Pharmacol 4: 218-226.
22. Valentino RJ, Foote SL, Aston-Jones G (1983). Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res 270: 363-367.
23. Vale W, Spiess J, Rivier C, Rivier J (1981). Characterization of a 41-residue bovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394-1397. (Pubitemid 12243637)
24. Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T (2005). FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem 280: 4609-4616. (Pubitemid 40288629)